Combination Treatment of tPA and Apyrase for Stroke

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,107,150.00
Award Year:
2010
Program:
SBIR
Phase:
Phase II
Contract:
2R44NS060175-02A1
Agency Tracking Number:
NS060175
Solicitation Year:
2010
Solicitation Topic Code:
NINDS
Solicitation Number:
PHS2010-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 4041 Forest Park Avenue, SAINT LOUIS, MO, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(312) 339-8455
RCHEN@APT-THERAPEUTICS.COM
Business Contact:
RIDONG CHEN
(312) 339-8455
rchen@apt-therapeutics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. Using a protein informatics approach, we have successfully engineered a human apyrase which exhibits significantly higher enzymatic activity and platelet inhibition than the wild-type apyrases. Importantly, the optimized apyrase conferred cerebroprotection against experimental stroke while preventing intracerebral hemorrhage. With the Phase II grant support, we will determine whether apyrase therapy is more effective while having lower bleeding risk than aspirin and a GPIIb/IIIa receptor antagonist, in combination with r-tPA for thrombolysis of stroke occlusion. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to validate whether human apyrase improves efficacy and reduce cerebral hemorrhage associated with thrombolytic treatment of ischemic stroke.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government